Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target

RL Jensen - Journal of neuro-oncology, 2009 - Springer
Hypoxia is implicated in many aspects of tumor development, angiogenesis, and growth in
many different tumors. Brain tumors, particularly the highly aggressive glioblastoma …

[HTML][HTML] A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology

…, AC Beck, SS Buys, C Vaklavas, JH Ward, RL Jensen… - Nature cancer, 2022 - nature.com
Abstract Models that recapitulate the complexity of human tumors are urgently needed to
develop more effective cancer therapies. We report a bank of human patient-derived xenografts …

Inhibition of hypoxia inducible factor-1α (HIF-1α) decreases vascular endothelial growth factor (VEGF) secretion and tumor growth in malignant gliomas

RL Jensen, BT Ragel, K Whang, D Gillespie - Journal of neuro-oncology, 2006 - Springer
Introduction Hypoxia inducible factor-1α (HIF-1α) regulates vascular endothelial growth
factor (VEGF), the presumed principal mediator of angiogenesis in malignant gliomas, under …

Safety and feasibility of convection-enhanced delivery of Cotara for the treatment of malignant glioma: initial experience in 51 patients

SJ Patel, WR Shapiro, DW Laske, RL Jensen… - …, 2005 - journals.lww.com
… Carolina Neurosurgery and Spine: Anthony L. Asher, MD Medical University of South Carolina:
Sunil J. Patel, … Laske, MD University of Utah Medical Center: Randy L. Jensen, MD, Ph.D. …

Hypoxia‐regulated protein expression, patient characteristics, and preoperative imaging as predictors of survival in adults with glioblastoma multiforme

…, GB Ellsworth, KL Salzman, AY Kinney, RL Jensen - Cancer, 2008 - Wiley Online Library
BACKGROUND. Regions of hypoxia within glioblastoma multiforme (GBM) are common and
may influence a tumor's aggressiveness, response to treatment, and the patient's overall …

A practical review of prognostic correlations of molecular biomarkers in glioblastoma

…, JA Neil, J Guan, MA Mahan, H Colman, RL Jensen - Neurosurgical …, 2015 - thejns.org
Despite extensive efforts in research and therapeutics, achieving longer survival for patients
with glioblastoma (GBM) remains a formidable challenge. Furthermore, because of rapid …

Subependymomas: an analysis of clinical and imaging features

…, AG Osborn, K Whang, JJ Townsend, RL Jensen… - …, 2006 - journals.lww.com
OBJECTIVE: Subependymomas are slow-growing, benign tumors usually found incidentally
in the fourth ventricle at autopsy. They are typically associated with the ventricular system …

New molecular considerations for glioma: IDH, ATRX, BRAF, TERT, H3 K27M

M Karsy, J Guan, AL Cohen, RL Jensen… - Current neurology and …, 2017 - Springer
Purpose of Review This review will discuss the role of several key players in glioma
classification and biology, namely isocitrate dehydrogenase 1 and 2 (IDH1/2), alpha thalassemia/…

Preoperative dynamic contrast-enhanced MRI correlates with molecular markers of hypoxia and vascularity in specific areas of intratumoral microenvironment and is …

RL Jensen, ML Mumert, DL Gillespie… - Neuro …, 2014 - academic.oup.com
Background Measures of tumor vascularity and hypoxia have been correlated with glioma
grade and outcome. Dynamic contrast-enhanced (DCE) MRI can noninvasively map tumor …

Dose fractionation in stereotactic radiotherapy for parasellar meningiomas: radiobiological considerations of efficacy and optic nerve tolerance

DC Shrieve, L Hazard, K Boucher, RL Jensen - Journal of neurosurgery, 2004 - thejns.org
Object. Benign meningiomas have been shown to be equally well controlled with single-dose
radiosurgery (15 Gy) and fractionated doses of 54 Gy in 30 fractions after adequate follow …